Compare Citius Pharmaceuticals Inc (CTXR) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs TKO Group Holdings Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while TKO Group Holdings Inc trades at $186.03 (market cap $13.84B). The key difference: TKO Group Holdings Inc is far larger — about 945.4× Citius Pharmaceuticals Inc's market cap, and TKO Group Holdings Inc pays a 1.69% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TKO | |
|---|---|---|
Market Cap | $14.64M | $13.84B |
Sector | Health | Technology |
52-Week High | $1.82 | $224.96 |
52-Week Low | $0.53 | $155.61 |
Enterprise Value | $10.86M | $18.01B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
TKO Group Holdings trades at $180.96, down 1.87% on the day, with mixed technical signals showing bearish moving averages but bullish oscillators. The company reported strong Q1 2026 earnings beat but missed Q3 and Q4 2025 expectations. Revenue grew to $4.74B in 2025 with net income of $195.4M, while 2026 projections show continued growth to $5.1B revenue. Recent developments include successful international events and an $800M share repurchase completion.
Wall Street maintains strong bullish sentiment with 89% buy ratings and $228 consensus price target, representing 26% upside. Key risks include execution on earnings guidance and competitive pressures in sports entertainment. The company's premium valuation (P/E 68.6) requires sustained growth delivery, while positive cash flow trends and dividend payments provide shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
